A pathologist's assessment is considered the "gold standard" for deciding whether cancer is present or absent and whether atypical epithelium is reported. However, extensive variation between pathologists has been documented, with disagreement in the diagnosis of atypical ductal hyperplasia (ADH) in more than 50% of cases and a misclassification rate for cases designated by experts as ductal carcinoma in situ (DCIS) of 17%. We propose to evaluate the extent of variability, its sources and its impact on women undergoing breast biopsy. Our research will also evaluate possible techniques to improve accuracy, such as double reading. To accomplish our study aims we will develop four diagnostic test sets, weighted to include a high percentage of cases with ADH and DCIS, as defined by a panel of international experts. More than 100 pathologists from multiple regions of the U.S. will independently review the same test sets during two phases, separated by 6 months.
Our specific aims are: 1. To assess the accuracy of pathologists in the interpretation of breast pathology specimens and quantify the extent and possible sources of intra- and inter-observer variability. 2. To assess whether the addition of independent double reading by two pathologists on all or a subset of cases can improve the accuracy of interpretation of breast pathology specimens. 3. To quantify the implications of variability among pathologists'interpretations of breast specimens on short-term patient care and associated resource utilization within the U.S. population. We hypothesize that the following characteristics are associated with lower accuracy: a) Patient characteristics (age <50 years, African American, dense breast, extensive background proliferative change, ADH and DCIS interpretation): and b) Pathologist characteristics (e.g., less clinical experience). In summary, we will evaluate the accuracy of breast pathology interpretation, emphasizing the classification of ADH and DCIS, where previous studies reveal a concerning degree of diagnostic errors. This large multi- center study of community pathologists addresses a topic that has growing clinical importance. Our research team includes international experts in breast pathology, statistical measurement of test accuracy, and studies of observer variability in clinical medicine, as well as an advisory committee of clinical experts in breast disease. The proposed work is innovative in that we will go beyond simply quantifying the existence of errors. We will study patient and physician characteristics associated with inaccurate diagnoses. We will then evaluate methods for improving health care delivery using double reading. Finally, we will use a systematic method to make projections from our data to clinical implications of inaccurate diagnoses.
Surprisingly little research has investigated the accuracy of pathologists in diagnosing cancer, yet the pathologists'assessment is the gold standard for deciding whether cancer is present or absent and, in the case of breast tissue, whether atypical cells are noted. We propose a series of studies to evaluate the extent and impact of variability in breast pathology interpretation. We will also evaluate the impact of double reading on overall accuracy.
|Allison, Kimberly H; Reisch, Lisa M; Carney, Patricia A et al. (2014) Understanding diagnostic variability in breast pathology: lessons learned from an expert consensus review panel. Histopathology 65:240-51|
|Geller, Berta M; Nelson, Heidi D; Carney, Patricia A et al. (2014) Second opinion in breast pathology: policy, practice and perception. J Clin Pathol 67:955-60|
|Feng, Sherry; Weaver, Donald L; Carney, Patricia A et al. (2014) A framework for evaluating diagnostic discordance in pathology discovered during research studies. Arch Pathol Lab Med 138:955-61|
|Oster, Natalia V; Carney, Patricia A; Allison, Kimberly H et al. (2013) Development of a diagnostic test set to assess agreement in breast pathology: practical application of the Guidelines for Reporting Reliability and Agreement Studies (GRRAS). BMC Womens Health 13:3|